WilckenDEL, GuptaVJ, BettsAK. Homocysteine in the plasma of renal transplant recipients: effect of cofactors for methionine metabolism. Clin Sci1981; 61:743–9.
2.
ArnadottirM, BrattströmL, SimonsenO, . The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concetrations in dialysis patients. Clin Nephrol1993; 40:236–40.
3.
AmadottirM, HultbergB, Nilsson-EhleP, ThysellH. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest1996; 56:41–6.
4.
BostomAG, SheminD, LapaneKL, . High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int1996; 49:147–52.
5.
RobinsonK, GuptaA, DennisV, . Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation1996; 94:2743–8.
6.
TamuraT, JohnstonKE, BergmanSM. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol1996; 7:2414–8.
7.
GreenR, JacobsenDW. Clinical implications of hyperhomocysteinemia. In: BaileyLB, ed. Folate in health and disease. New York: Marcel Dekker, 1995:75–122.
8.
IbelsLS, StewartJH, MahonyJF, NealeFC, SheilAGR. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis. Quart J Med1977; 46:197–214.
9.
DennisVW, RobinsonK. Homocysteinemia and vascular disease in end-stage renal disease. Kid Inter1996; 50 (suppl. 57): S-11–S-17.
10.
BostomAG, LathropL. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerosis outcomes. Kidney Int1997; 52:10–20.
11.
MuddSH, LevyHL, SkovbyF. Disorders of transsulfuration. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The meta-bolic and molecular basis of inherited disease. Seventh edition. New York: McGraw-Hill, 1995; 1279–327.
12.
McCullyKS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol1969; 56:111–28.
13.
JacquesPF, BostomAG, WilliamsRR, . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation1996; 93:7–9.
14.
FödingerM, MannhalterC, WölflG, . Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int1997; 52:517–23.
15.
GuttormsenAB, UelandPM, SvarstadE, RefsumH. Kinetic basis of hyperhomocysteinemia in patients with chronic failure. Kidney Int1997; 52:495–502.
16.
BostomA, BrosnanJT, HallB, NadeauMR, SelhubJ. Net uptake of plasma homocysteine by the rat kidney in vivo.Atherosclerosis1995; 116:59–62.
17.
LivantEJ, TamuraT, JohnstonKE, . Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem1994; 5:504–8.
18.
DescombesE, HanckAB, FellayG. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int1993; 43:1319–28.
19.
KasamaR, KochT, Canals-NavasC, PitoneJM. Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of literature. Am J Kidney Dis1996; 27:680–6.
20.
OnoK, HisasueY. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy?Clin Nephrol1992; 38:290–2.
21.
GentileMG, FellinG, CofanoF, . Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin Nephrol1993; 40:315–20.
22.
KontessisP, JonesS, DoddsR, . Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kid Inter1990; 38:136–44.
